Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers.

NPJ breast cancer·2024
Same author

Systemic Therapy in Older Patients With High-Risk Disease.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2023
Same author

PORTRET, a more inclusive portrait of the older population with breast cancer.

The lancet. Healthy longevity·2022
Same author

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

The New England journal of medicine·2021
Same author

Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).

The Lancet. Oncology·2021
Same author

Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement.

JAMA oncology·2021

Related Experiment Video

Updated: Jul 13, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Safety and efficacy of ET-743: the French experience.

Etienne G C Brain1

  • 1Department of Medical Oncology, Cancer Centre René Huguenin, 35 rue Dailly, 92210 Saint-Cloud, France. e.brain@stcloud-huguenin.org

Anti-Cancer Drugs
|August 14, 2002
PubMed
Summary

Ecteinascidin-743 (ET-743) shows clinical benefit in advanced soft-tissue sarcoma (STS) patients, demonstrating disease stabilization and manageable toxicity. This study confirms ET-743

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)
04:11

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

Published on: June 9, 2026

Related Experiment Videos

Last Updated: Jul 13, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)
04:11

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

Published on: June 9, 2026

Area of Science:

  • Pharmacology and Clinical Oncology

Background:

  • Initial Phase I studies and compassionate use of ecteinascidin-743 (ET-743) indicated clinical benefit in sarcoma patients.
  • Patients in the Phase II study had advanced, anthracycline-pretreated soft-tissue sarcoma (STS), with many resistant to standard chemotherapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of ET-743 in patients with advanced soft-tissue sarcoma (STS) resistant to anthracyclines.
  • To assess response rates, survival, and toxicity profiles of ET-743 in a heavily pretreated STS population.

Main Methods:

  • A French multicenter Phase II study administered ET-743 at 1500 micrograms/m2 every 3 weeks via continuous 24-hour infusion.
  • 54 patients with advanced STS, including leiomyosarcoma and visceral/uterine tumors, were enrolled between February 1999 and January 2001.
  • Safety and efficacy were assessed, including response rates, progression-free survival, overall survival, and adverse events.

Main Results:

  • Of 52 evaluable patients, 6% achieved partial response, 8% minor response, and 42% disease stabilization.
  • Median survival was approximately 11 months, with a 6-month progression-free survival of 26.5% and a 12-month overall survival of nearly 50%.
  • Frequent toxicities included reversible neutropenia and transaminitis (grade 3/4); severe rhabdomyolysis occurred in two cases. No cumulative toxicity was observed.

Conclusions:

  • ET-743 demonstrates significant activity and manageable toxicity in patients with advanced, pretreated soft-tissue sarcoma (STS).
  • The drug's non-cumulative and reversible side effects support its role in treating advanced STS.
  • Response rates were not influenced by metastatic site, tumor size, or prior anthracycline sensitivity.